Alimera Sciences (NASDAQ:ALIM) received a $2.00 price target from equities researchers at HC Wainwright in a research report issued on Wednesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 88.68% from the stock’s previous close.
A number of other brokerages have also recently issued reports on ALIM. TheStreet upgraded shares of Alimera Sciences from a “d-” rating to a “c-” rating in a report on Tuesday, November 6th. Zacks Investment Research upgraded shares of Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a report on Friday, November 9th. Finally, ValuEngine upgraded shares of Alimera Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $2.25.
Shares of NASDAQ ALIM opened at $1.06 on Wednesday. The stock has a market cap of $77.09 million, a PE ratio of -3.66 and a beta of 2.17. Alimera Sciences has a 1 year low of $0.72 and a 1 year high of $1.34.
About Alimera Sciences
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
Recommended Story: Why is the LIBOR significant?
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.